Country 2 Country 4 Cancer (C2C4C) 2023

The 2023 Country 2 Country 4 Cancer ride organised by Bristol Myers Squibb will feature more than 90 of the company's employees cycling in five European countries from 1-18th September in support of the Union for International Cancer Control (UICC) and selected members to raise funds with the aim of accelerating the fight against cancer and facilitating a better life for cancer patients.

Germany Day 2 BMS Riders

For the 8th year, the 2023 edition of the Country 2 Country 4 Cancer (C2C4C) ride will feature more than 90 Bristol Myers Squibb employees riding in Germany, Switzerland, France, Spain and the United Kingdom for nearly 2,200 kilometres from 1-18 September.

The 18-day event involves six teams each cycling a three-day segment. This year we celebrate 10 years of C2C4C and riding for patients, with the inaugural event taking place in the United States in 2014.

Since 2016, nearly 550 Bristol Myers Squibb employees in Europe have raised more USD2.6 million through the C2C4C ride.  

In this 2023 edition, six teams will feature riders participating from 19 countries including Belgium, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Norway, Portugal, Spain, Sweden, Switzerland, United Kingdom, the United States and for the first time, participants from the Czech Republic, Hungary, Poland and Romania. The goal of C2C4C is to raise awareness for cancer research and European cancer organisations who are members of UICC. 

Who are the riders

The participants are novice riders who have committed themselves to 5 months of intensive training to complete their portion of the ride. Some are cancer survivors, others have witnessed the devastating impact of cancer on friends and family. All are dedicated Bristol Myers Squibb employees who are riding to help raise funds to fight against cancer by supporting European cancer organisations, who are members of UICC.

About Bristol Myers Squibb

Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases.

Why raise funds for cancer organisations

Cancer is among the leading causes of death worldwide. Each year, there are 18.1 million new cases and 9.6 million cancer-related deaths worldwide, and these numbers are growing. 

This is why Bristol Myers Squibb has chosen to support the UICC and its members in their mission to reduce the global cancer burden and integrate cancer control into the world health and development agenda. 

Encourage your colleagues, families and friends to donate, as cancer affects us all. Each team rides and raises funds for members of the Union for International Cancer Control. 

How to support the C2C4C 2023 ride

Click on the charity of your country below to support and donate to a local cancer patient organisation. Donations are open as of 5 June 2023.

Leg Team

Ride Date

Country Teams Route Charity Partner

Sept. 1-3 2023


Munich, Germany to Boudry, Switzerland

Initiative Krebskranke Kinder München e.V.


Sept. 4-6 2023

Italy, Switzerland & Austria

Boudry, Switzerland to Nimes, France

Italy: Women Against Lung Cancer in Europe (WALCE) 

Switzerland & Austria: CanSearCH


Sept. 7-9 2023

Denmark, Finland, Norway & Sweden 

Nimes, France to Girona, Espagne

Denmark: SMIL-Fonden

Finland: Association of Cancer Patients in Finland

Norway: AKTIV Mot Kreft

Sweden: Barncancerfonden


Sept. 10-12 2023

Spain & Portugal 

Girona, Espagne to Toulouse, France

Asociación Española Contra el Cáncer 


Sept. 13-15 2023


Toulouse France to Paris



Sept. 16-18 2023

UK & Ireland

Netherlands & Belgium 

Paris, France to Uxbridge, UK

UK-Ireland: Maggie's Cancer Centres and The Irish Cancer Society 

Netherlands: Villa Joep 

Belgium: Belgium Foundation Against Cancer

Romania flat rounded icon


Riders in multiple segments

Asociatia Daruieste Viata / Give Life Association


“I continue to be amazed and inspired by our Country 2 Country 4 Cancer ride. Our motto, ‘It’s more than a bike ride,’ has deep meaning to our employees as it truly speaks to the passion and focus of our work. We put the patients at the center of what we do and raising funds to advance cancer research is one of the most powerful and important examples of making a difference for our employees and most especially for patients and their families in need.”
“This year’s edition of C2C4C ride is an occasion to celebrate the 10th anniversary of this fundraising adventure. UICC has been with Bristol Myers Squibb for most of this incredible journey and we are grateful as ever on behalf of our members for the company’s generosity in supporting cancer research and people living with cancer. We certainly look forward again to this year’s ride!”
Dr Cary Adams, CEO of UICC

Past editions

Commemorating a decade of Bristol Myers Squibb employees cycling for cancer research

Group of cyclists on a road through a corn field, with t-shirts featuring Bristol Myers Squibb (BMS) and the Country 2 Country 4 Cancer ride
Read more

More epic cycling rides in 2022 by BMS to fundraise for UICC members

Employees of Bristol Myers Squibb riding for the Ger Power Irish team in the 2021 Country to Country for Cancer ride
Read more

Inside look at a record fundraise for the 2021 C2C4C ride

C2C4C ride - Netherland team in a huddle
Read more

Continued support for UICC members despite C2C4C cancellation

© Bristol-Myers Squibb | C2C4C ride
Read more

Bristol-Myers Squibb team completes fundraising ride across Europe

2019 C2C4C riders arrive at Bristol-Myers Squibb office in London, UK on 27 Sept. 2019
Read more

95 Bristol-Myers Squibb cyclists set off on a 3,600km journey across Europe for cancer research

C2C4C bikers cheering
Read more

Bristol-Myers Squibb Employees Cycle for Cancer Research

Zach Stowlow
Read more

Bristol-Myers Squibb employees rode over 3,600 km across Europe for cancer patients

C2C4C - Bristol-Myers Squibb
Read more

Bristol-Myers Squibb employees raise funds for UICC members

© Bristol-Myers Squibb | C2C4C ride
Read more

Last update

Tuesday 05 September 2023

Share this page